Nivolumab (Opdivo®) is a Health Canada-approved immunotherapy for the treatment of kidney cancer and works by targeting a molecule called PD-1. Blocking the PD-1 molecule helps prime the body’s immune defences to more effectively target and destroy cancer cells; these therapies are often called immune checkpoint inhibitors (ICIs).
BMS-986340 targets a newly identified immune checkpoint molecule called CCR8. CCR8 is highly expressed on specialized immune cells that act as buffers to reduce the intensity of immune reactions. However, in cancer, this prevents robust anti-tumour immune activity. Therapies that block CCR8 may therefore be able to enhance anti-tumour immune activity by preventing this buffering.
Since this drug is still in the clinical trial phase, it has the placeholder name BMS-986340 rather than a commercial trade name.
This is a phase 1/2 study that will investigate the safety and effectiveness of BMS-986340 either alone or in combination with Nivolumab in patients with several different cancer types, including kidney cancer.
The treatment you receive will be assigned at random by the doctor overseeing your care.
Group 1: BMS-986340 alone
Group 2: BMS-986340+ Nivolumab
There is no control group in the study, so there will be no “placebo”, and all eligible patients will receive treatment.
- Advanced kidney cancer that cannot be removed by surgery
- Prior receipt of anti-PD(L)-1 immunotherapy (e.g. Pembrolizumab or Nivolumab)
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer||Principal InvestigatorNot Given||LocationVancouver, BC||Trial StatusNot yet recruiting|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorNot Given||LocationEdmonton, AB||Trial StatusRecruiting|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorNot Given||LocationHamilton, ON||Trial StatusNot yet recruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorNot Given||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreThe Ottawa Hospital||Principal InvestigatorNot Given||LocationOttawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreMontreal University Hospital (CHUM)||Principal InvestigatorNot Given||LocationMontreal, QC||Trial StatusRecruiting|